GPCR therapeutic monoclonal antibodies
SYnAbs and Domain Therapeutics enter into a strategic partnership for the discovery and development of therapeutic antibodies targeting complex G Protein Coupled Receptor targets for immuno-oncology indications
From the discovery of an unique peptide ligand to the clinical relevance of ETA and ETB receptors and the current therapeutic pipeline of small molecules and monoclonal antibodies targeting these GPCR transmembrane proteins
SYnAbs can help you develop therapeutic antibody-drug conjugates by specifically targeting transmembrane proteins using innovative proprietary technologies.
SYnAbs discovers antibodies to transmembrane proteins including GPCR chemokine receptors thanks to unique cell immunization technology and expertise
SYnAbs develops therapeutic monoclonal antibodies with agonistic or antagonistic effects to highly homologous G Protein-Coupled Receptors transmembrane proteins
SYnAbs are unique therapeutic effector monoclonal antibodies targeting anaphylatoxin C3aR GPCR. First-in-class functional antibody targeting complex transmembrane proteins and G protein-coupled receptors.
The Complement System and its druggable targets by antibodies: C3aR, C5aR GPCR membrane receptors, C3, C4, C5 ligands
Untapped therapeutic potential of orphan GPCR and SYnAbs functional monoclonals anti-GPCR. Generation of new antibody therapeutics targeting orphan membrane receptors.
SYnabs generate therapeutic monoclonal antibodies against CC chemokine receptors thanks to DNA, cell immunization strategies, unique rat-LOU species and proprietary adjuvant
SYnAbs develops anti-chemokine receptors monoclonal antibodies with therapeutic effect for Biotech and Pharma companies